DAHUA-TECHNOLOGY
Dahua Technology, a world-leading video-centric smart IoT solution and service provider, has been accelerating the innovation and exploration of Full-color Technology. Featuring TiOC, Panoramic, Zoom and 4K, the new generation of Dahua full-color series provides a wide range of low-light solutions that integrate different intelligent technologies to solve pain points in various scenarios, allowing installers and end users to choose the ideal solution that best suits their needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121005376/en/
Inadequate availability of light is one of the major challenges of every monitoring system. Images taken under such lighting condition are often not clear, have detail loss, and even contain noise, making it difficult to detect or trace back targets in case of an event. The Dahua Full-color cameras were developed to address these demanding monitoring challenges. With remarkable offerings such as dual lens, vari-focal lens, 4K resolution, and AI features, this technology offers a wide-range of products and solutions that can effectively solve the arduous monitoring pain points of end-users and provide clear and vivid images of the monitored scene 24/7. (Photo: Business Wire)
Full-color + TiOC: effective deterrent against intruders
The Dahua TiOC (three-in-one camera) integrates Smart Dual Illuminators, Active Deterrence, and AI to offer a pro-active monitoring solution that can effectively warn off intruders. The combination of Dahua’s industry-leading full-color technology with powerful AI functions and real-time Active Deterrence warnings makes it suitable for places that require 24/7 security, such as villas, shops, warehouses, etc., helping to reduce false alarm rates, improve target search efficiency, generally optimize system operation, and reduce costs.
Full-color + Panoramic: the whole scene in vivid color
The Dahua Full-color Dual Lens 180° Panoramic PTZ & IPC are equipped with dual sensors that deliver a 180-degree field of view. It adopts the Dahua pixel-level seamless fusion algorithm to splice images into horizontal 180° monitoring scene, providing users with brilliant full-color and panoramic images. Featuring wide-area coverage, it is an excellent alternative to daunting installation of multiple cameras just to cover a large scene. Thanks to Full-color Technology, the intelligent panoramic camera can provide clear color images even at night, which is essential for 24/7 continuous monitoring in large application scenarios such as squares, hallways, and parking lots.
Full-color + ZOOM: vari-focal zoom in with vivid color
The Dahua Full-color Vari-focal Camera boasts approx. 5x optical zoom capability and auto-focus function. These cameras provide clear monitoring scene details even after zooming in, capture vivid color images in dark environments, and also allow users to directly adjust the camera’s focus according to the actual scene, which is convenient and time-saving.
Full-color + 4K: Realistic 4K UHD image quality
The Dahua Full-color 4K Camera delivers enhanced color images and video footages 24/7. It adopts 1/1.2” image sensor (currently Dahua's best low-light IPC sensor) that provides 110% pixel size increase compared to common 8MP sensor. Combined with a F1.0 large aperture, more available light can be captured to provide clear and vivid images, which is conductive to accurate video analysis.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005376/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom